BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives “Outperform” Rating from Royal Bank of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Friday,Benzinga reports. They presently have a $11.00 target price on the biotechnology company’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 67.94% from the company’s current price.

Other equities research analysts have also issued reports about the company. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday. Finally, Evercore ISI boosted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Performance

NASDAQ:BCRX traded up $0.14 during midday trading on Friday, reaching $6.55. 469,014 shares of the stock traded hands, compared to its average volume of 2,796,907. The stock has a market capitalization of $1.37 billion, a P/E ratio of -10.73 and a beta of 1.75. The company has a fifty day moving average of $7.99 and a 200 day moving average of $7.75. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The company’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 earnings per share. On average, analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC boosted its position in shares of BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $46,000. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $48,000. Finally, KBC Group NV increased its position in BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.